EUCTR2005-003242-34-ES进行中（未招募）不适用
Secondary Prevention of Small Subcortical Strokes - SPS3
ational Institutes of Neurological Disorders: Stroke0 个研究点目标入组 2,500 人开始时间: 2012年9月11日最近更新:
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,500
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •One of the following lacunar stroke clinical syndromes (adapted from Fisher) lasting > 24 hrs: a. Pure motor hemiparesis (PMH) b. Pure sensory stroke c. Sensorimotor stroke d. Ataxic hemiparesis e. Dysarthria-clumsy hand syndrome f. Hemiballism g. PMH with facial sparing h. PMH with horizontal gaze palsy i. PMH with contralateral III palsy j. PMH with contralateral VI palsy k. Cerebellar ataxia with contralateral III palsy l. Pure dysarthria 2. Absence of signs or symptoms of cortical dysfunction such as aphasia, apraxia, agnosia, agraphia, homonymous visual field defect, etc. 3. No ipsilateral cervical carotid stenosis (?50%) by a reliable imaging modality done in an approved laboratory within 6 months of the qualifying S3, if hemispheric. 4. No major-risk cardioembolic sources requiring anticoagulation or other specific therapy. Minor-risk cardioembolic sources will be permitted if anticoagulation is not prescribed by the patient?s primary care physician. Major risk sourcesa: Minor risk sourcesc: ? Atrial fibrillation ? Mitral valve prolapse + myxomatous changes ? Mitral stenosis ? Mitral annular calcification ? Prosthetic cardiac valves ? Patent foramen ovaled ? Recent (< 3 mos transmural MI) ? Atrial septal aneurysm ? LV thrombus, especially if mobile or protruding ? LV wall abnormalities (without thrombus) ? Atrial myxomas ? Calcific aortic stenosis ? Infective endocarditis ? Non-ischemic dilating cardiomyopathiesb ? Marantic endocarditis aAssociated with a substantial absolute risk of stroke, firmly linked to an embolic mechanism bRisk varies with the type and severity cAssociated with a low or uncertain absolute risk of initial or recurrent stroke or are incompletely established as direct embolic source dIf associated with pulmonary hypertension with sustained right-to-left shunting and venous source of emboli, it is a major risk.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Disabling stroke (Modified Rankin Scale ?4) 2. Previous intracranial hemorrhage (excluding traumatic) or hemorrhagic stroke 3. Age under 40 years 4. High risk of bleeding (e.g. recurrent GI or GU bleeding, active peptic ulcer disease, etc) 5. Anticipated requirement for long-term use of anticoagulants (e.g. recurrent DVT) or other antiplatelets 6. Prior cortical stroke (diagnosed either clinically or by neuroimaging), or prior cortical or retinal TIA 7. Prior ipsilateral carotid endarterectomy 8. Impaired renal function: characterized by estimated GFR < 40 9. Intolerance or contraindications to aspirin or clopidogrel (including thrombocytopenia, prolonged INR) 10. A score < 24 (adjusted for age and education; adapted from Crum et al, 1993; n = 18,056)
研究者
相似试验
已完成
不适用
Secondary Prevention of Small Subcortical Vascular Brain Attacks-I639 Cerebral infarction, unspecifiedCerebral infarction, unspecifiedI639PER-076-05FUNDACION CAYETANO HEREDIA,186
未知
不适用
Secondary Prevention of Cerebral Infarction Epidemiological Study on Cerebral Microbleedscerebral infactionJPRN-UMIN000001230SCIENCE Study Protocol Comittee4,000
招募中
不适用
Prevention of secondary stroke by risk factor control and medication adherenceCTRI/2021/10/037432Department of Health and Family Welfare
已完成
不适用
Evaluation of Secondary Prevention of Stroke Study in the Outpatient Cliniccerebrovascular accident10007963StrokeNL-OMON35302Academisch Medisch Centrum200
进行中（未招募）
1 期
Prevention of Stroke in Survivors of Brain Bleeding with Atrial FibrillatioEUCTR2018-002176-41-ITImperial College of Science, Technology and Medicine654